QQ客服 官方微博 反馈留言

	Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
	Yue, Dongsheng; Xu, Shidong; Wang, Qun; Li, Xiaofei; Shen, Yi; Zhao, Heng; Chen, Chun; Mao, Weimin; Liu, Wei; Liu, Junfeng
刊名	LANCET RESPIRATORY MEDICINE
	2018
卷号	6期号:11
ISSN号	2213-2600
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3605242
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Yue, Dongsheng,Xu, Shidong,Wang, Qun,et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial[J]. LANCET RESPIRATORY MEDICINE,2018,6(11).
APA	Yue, Dongsheng.,Xu, Shidong.,Wang, Qun.,Li, Xiaofei.,Shen, Yi.,...&Wang, Changli.(2018).Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial.LANCET RESPIRATORY MEDICINE,6(11).
MLA	Yue, Dongsheng,et al."Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial".LANCET RESPIRATORY MEDICINE 6.11(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。